Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

– Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology –


–...

Related Keywords

Missouri ,United States ,San Francisco ,California ,Portland ,Oregon ,Switzerland ,Bellinzona ,Ticino , ,Nasdaq ,Vir Biotechnology Inc ,Exchange Commission ,Vir Biotechnology ,Marianne De Backer ,Chief Executive ,Private Securities Litigation Reform Act ,Markets ,